These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 22459268)

  • 1. Response to "Ipilimumab (Yervoy) and the TGN1412 catastrophe".
    Curran MA; Callahan MK; Subudhi SK; Allison JP
    Immunobiology; 2012 Jun; 217(6):590-2. PubMed ID: 22459268
    [No Abstract]   [Full Text] [Related]  

  • 2. Ipilimumab (Yervoy) and the TGN1412 catastrophe.
    Bakacs T; Mehrishi JN; Moss RW
    Immunobiology; 2012 Jun; 217(6):583-9. PubMed ID: 21821307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Ctla-4 blockade: a new hope for the immunotherapy of malignant melanoma].
    Lotem M; Merims S; Frank S; Ospovat I; Peretz T
    Harefuah; 2012 Oct; 151(10):585-8, 604. PubMed ID: 23316667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
    Graziani G; Tentori L; Navarra P
    Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delayed dermatologic hypersensitivity reaction secondary to ipilimumab.
    Ludlow SP; Kay N
    J Immunother; 2015 May; 38(4):165-6. PubMed ID: 25839442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.
    Vétizou M; Pitt JM; Daillère R; Lepage P; Waldschmitt N; Flament C; Rusakiewicz S; Routy B; Roberti MP; Duong CP; Poirier-Colame V; Roux A; Becharef S; Formenti S; Golden E; Cording S; Eberl G; Schlitzer A; Ginhoux F; Mani S; Yamazaki T; Jacquelot N; Enot DP; Bérard M; Nigou J; Opolon P; Eggermont A; Woerther PL; Chachaty E; Chaput N; Robert C; Mateus C; Kroemer G; Raoult D; Boneca IG; Carbonnel F; Chamaillard M; Zitvogel L
    Science; 2015 Nov; 350(6264):1079-84. PubMed ID: 26541610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody).
    Akhtari M; Waller EK; Jaye DL; Lawson DH; Ibrahim R; Papadopoulos NE; Arellano ML
    J Immunother; 2009 Apr; 32(3):322-4. PubMed ID: 19242368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review.
    Juszczak A; Gupta A; Karavitaki N; Middleton MR; Grossman AB
    Eur J Endocrinol; 2012 Jul; 167(1):1-5. PubMed ID: 22495490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ipilimumab-induced autoimmune pancytopenia in a case of metastatic melanoma.
    du Rusquec P; Saint-Jean M; Brocard A; Peuvrel L; Khammari A; Quéreux G; Dréno B
    J Immunother; 2014; 37(6):348-50. PubMed ID: 24911795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatic mutations and immunotherapy outcome with CTLA-4 blockade in melanoma.
    Boussiotis VA
    N Engl J Med; 2014 Dec; 371(23):2230-2. PubMed ID: 25409261
    [No Abstract]   [Full Text] [Related]  

  • 11. [When CRAF takes over BRAF in melanoma].
    Dumaz N; Bagot M; Bensussan A
    Med Sci (Paris); 2011 Oct; 27(10):817-9. PubMed ID: 22027417
    [No Abstract]   [Full Text] [Related]  

  • 12. Therapeutic use of anti-CTLA-4 antibodies.
    Blank CU; Enk A
    Int Immunol; 2015 Jan; 27(1):3-10. PubMed ID: 25038057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour immunology: Intestinal bacteria are in command.
    Alderton GK
    Nat Rev Immunol; 2016 Jan; 16(1):5. PubMed ID: 26655627
    [No Abstract]   [Full Text] [Related]  

  • 14. Melanoma immunotherapy: historical precedents, recent successes and future prospects.
    Raaijmakers MI; Rozati S; Goldinger SM; Widmer DS; Dummer R; Levesque MP
    Immunotherapy; 2013 Feb; 5(2):169-82. PubMed ID: 23413908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IMMUNOTHERAPY. Could microbial therapy boost cancer immunotherapy?
    Snyder A; Pamer E; Wolchok J
    Science; 2015 Nov; 350(6264):1031-2. PubMed ID: 26612936
    [No Abstract]   [Full Text] [Related]  

  • 16. [Orbital myositis associated with ipilimumab].
    Lecouflet M; Verschoore M; Giard C; Gohier P; Le Corre Y; Milea D; Martin L
    Ann Dermatol Venereol; 2013; 140(6-7):448-51. PubMed ID: 23773743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unexpected recalcitrant course of drug-induced erythema multiforme-like eruption and interstitial pneumonia sequentially occurring after nivolumab therapy.
    Nomura H; Takahashi H; Suzuki S; Kurihara Y; Chubachi S; Kawada I; Yasuda H; Betsuyaku T; Amagai M; Funakoshi T
    J Dermatol; 2017 Jul; 44(7):818-821. PubMed ID: 28295542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The conquest of melanoma by immunotherapy.
    Lejeune FJ
    Melanoma Res; 2015 Oct; 25(5):373-5. PubMed ID: 26173006
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunotherapy in melanoma: Recent advances and future directions.
    Franklin C; Livingstone E; Roesch A; Schilling B; Schadendorf D
    Eur J Surg Oncol; 2017 Mar; 43(3):604-611. PubMed ID: 27769635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ipilimumab-induced orbital inflammation resembling Graves disease with subsequent development of systemic hyperthyroidism from CTLA-4 receptor suppression.
    Borodic GE; Hinkle D
    Ophthalmic Plast Reconstr Surg; 2014; 30(1):83. PubMed ID: 24398505
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.